This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AstraZeneca Falls on Drug Setback

Updated from 8:35 a.m.

Shares in the U.K-based drugmaker AstraZeneca (AZN) fell Monday after an advisory committee of the Food and Drug Administration late Friday dealt a staggering blow to the company's experimental blood thinner Exanta, saying the risks of liver damage outweighed the benefits.

The panel rejected AstraZeneca's entire application that Exanta be approved for three uses related to preventing blood clots, Reuters reported Friday.

The FDA is expected to act on the panel's recommendations by late October. The agency doesn't have to follow its advisers' suggestions, but it usually does so.

Shares were off $1.60, or 3.7%, to $42.14.

AstraZeneca had asked the FDA to approve the drug for preventing blood clots in veins for patients undergoing knee-replacement surgery; preventing stroke and other clot-induced complications of the erratic heartbeat known as atrial fibrillation; and long-term prevention of blood clots in veins after a patient has gotten a standard blood clot treatment.

But once the advisory panel rejected the knee-replacement-surgery application, it was clear that Exanta was in trouble. Analysts had viewed knee surgery as Exanta's best chance because the European Union has approved the drug for preventing blood clots after elective knee and hip surgeries.

In the company's U.S. application, knee surgery would have only required, at most, 12 days of treatment with the drug, whereas the other indications would have required long-term use of Exanta.

In addition, the FDA panel rejected as inadequate the company's proposed monitoring plan to protect Exanta users against liver damage.

The advisory committee voted after markets had closed. AstraZeneca's stock closed Friday at $43.74, losing 66 cents, or 1.5%, on trading volume that was 6 times the daily average. But in after-hours trading, the stock was down another $1.29, or 3.3%.

On Thursday, an unfavorable FDA staff report used as guidance for the advisory committee sent the stock down 5.6% on trading volume that was 11 times greater than average. The report raised significant concerns about liver damage stemming from long-term use of Exanta.

AstraZeneca was hoping that the advisory committee would enable Exanta to become the first new oral anticoagulant in more than 60 years in the U.S . The "gold standard" is warfarin, a pill sold by several generic companies and also sold under the brand name Coumadin by Bristol-Myers Squibb (BMY). Exanta is easier to administer than Coumadin, which requires periodic blood tests to measure its effectiveness. The AstraZeneca drug doesn't interact with as many drugs and foods as Coumadin does.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs